VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two

October 8, 2012 12:48 PM EDT
Get Alerts VVUS Hot Sheet
Price: $1.16 --0%

Rating Summary:
    4 Buy, 8 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 12
Trade VVUS Now!
Join SI Premium – FREE
VIVUS (Nasdaq: VVUS) shares are higher on the session following improving payment metrics for its obesity drug Qsymia.

According to Bloomberg Industries, Qsymia's prescription insurer payment rate rose 5 points in its second week to 36 percent.

Initial estimates from the company called for a minimal initial coverage rate.

Bloomberg Industries noted that the news could be a boon for peer Arena Pharmaceuticals (Nasdaq: ARNA) and its Belviq. Traders are likely to keep an eye on Orexigen (Nasdaq: OREX), which is working on the weight-loss pill Contrave.

Shares of VIVUS are up 3 percent Monday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Trader Talk

Add Your Comment